Brenus Pharma has announced the publication of a scientific article in Frontiers in Oncology detailing the results of its novel “off-the-shelf” cancer treatment. The company’s innovative platform replicates patients’ relapsing conditions in the lab to train the immune system to combat evolving tumors. It utilizes a broad range of multi-specific targets, with the lead candidate being a proteomic-guided immunotherapy designed to treat advanced or metastatic colorectal cancer (CRC).
The results show that the murine surrogate treatment successfully inhibited tumor growth and enhanced survival in treated mice. It also demonstrated efficacy in a PD1-resistant model, increasing the infiltration of CD8+ T cells into cold tumors, with promising safety data. Additionally, the treatment’s in vitro exposure to standard care therapies led to the expression of cancer-related proteins, which were safely rendered immunogenic via haptenation (chemical tagging). This process boosts tumor antigen recognition, enabling immune activation against tumor cells upon intradermal injection.
The findings highlight Brenus Pharma’s platform’s potential to address CRC challenges, especially in cases where conventional immunotherapies, such as anti-PD1, are ineffective. The research was conducted in collaboration with leading academic and scientific partners.
“We have demonstrated the ability to generate a safe, anti-tumor immune response in a syngeneic mouse model, and the technology has now been adapted for human trials. This progress brings us closer to providing new therapeutic options for patients,” said Dr. George Alzeeb, Innovation Manager at Brenus Pharma.
